Skip to main content
Journal cover image

EGFRvIII as a promising target for antibody-based brain tumor therapy.

Publication ,  Journal Article
Kuan, CT; Wikstrand, CJ; Bigner, DD
Published in: Brain Tumor Pathol
2000

Cell surface receptors are attractive candidates for targeted therapy of cancer. Growth factors and their receptors play important roles in the regulation of cell division, development, and differentiation. Among those, the epidermal growth factor receptor (EGFR) was the first identified to be amplified and/or rearranged in malignant gliomas. The most common rearranged form, EGFR type III variant (EGFRvIII), has a deletion in its extracellular domain that results in the formation of a new, tumor-specific target found in glioblastoma multiforme, as well as in breast, ovarian, prostate, and lung carcinomas. Monoclonal antibodies have been developed with specific activity against this mutant receptor. These antibodies are internalized into the cell after receptor binding. Specific antibodies, either unarmed or armed with cytotoxic agents, including radioisotopes and toxins, have shown a promising role for EGFRvIII as a target for brain tumor therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Brain Tumor Pathol

DOI

ISSN

1433-7398

Publication Date

2000

Volume

17

Issue

2

Start / End Page

71 / 78

Location

Japan

Related Subject Headings

  • Neurology & Neurosurgery
  • Immunotoxins
  • Immunotherapy, Active
  • Humans
  • Glioblastoma
  • ErbB Receptors
  • Brain Neoplasms
  • Antineoplastic Agents
  • Antibodies, Neoplasm
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2000). EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol, 17(2), 71–78. https://doi.org/10.1007/BF02482738
Kuan, C. T., C. J. Wikstrand, and D. D. Bigner. “EGFRvIII as a promising target for antibody-based brain tumor therapy.Brain Tumor Pathol 17, no. 2 (2000): 71–78. https://doi.org/10.1007/BF02482738.
Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 2000;17(2):71–8.
Kuan, C. T., et al. “EGFRvIII as a promising target for antibody-based brain tumor therapy.Brain Tumor Pathol, vol. 17, no. 2, 2000, pp. 71–78. Pubmed, doi:10.1007/BF02482738.
Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 2000;17(2):71–78.
Journal cover image

Published In

Brain Tumor Pathol

DOI

ISSN

1433-7398

Publication Date

2000

Volume

17

Issue

2

Start / End Page

71 / 78

Location

Japan

Related Subject Headings

  • Neurology & Neurosurgery
  • Immunotoxins
  • Immunotherapy, Active
  • Humans
  • Glioblastoma
  • ErbB Receptors
  • Brain Neoplasms
  • Antineoplastic Agents
  • Antibodies, Neoplasm
  • Antibodies, Monoclonal